Faron Announces First Patient Dosed in BLAZE Investigator-Initiated ...
(PR-inside.com) First clinical evaluation of bexmarilimab plus nivolumab in patients with anti-PD-1-resistant solid tumors TURKU, FI / ACCESS Newswire / October 1, 2026 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN) , a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatment…
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


